CASI Pharmaceuticals Inc

NASDAQ:CASIUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States and throughout the world. It is also focused on acquiring, developing, and commercializing products that augment its hematology-oncology therapeutic focus as well as other areas of unmet medical need. The Company’s operations in China are conducted primarily through its subsidiaries, which include CASI Pharmaceuticals (China) Co., Ltd. (CASI China), which is wholly owned and is located in Beijing, China, and CASI Pharmaceuticals (Wuxi) Co., Ltd. (CASI Wuxi), which is located in Wuxi, China. Its commercial product, EVOMELA, is developed for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The Company’s other core hematology/oncology assets in its pipeline include CNCT19, BI-1206, CB-5339 and CID-103.

Contact Information

Headquarters

9620 Medical Center Dr Ste 300ROCKVILLE, MD, United States 20850-3396

Phone

240-864-2600

Fax

302-655-5049

Executives

Chairman of the Board, Chief Executive Officer

Wei-Wu He

President, President of CASI China, Interim Principal Financial Officer

Wei Zhang

Executive Vice President, Chief Medical Officer

Alexander Zukiwski

Independent Director

James Huang

Independent Director

Franklin Salisbury